2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-168462
    α-Glucosidase-IN-82 98%
    α-Glucosidase-IN-82 (compound 8l) is a potent inhibitor of α-Glucosidase, with the IC50 of 13.66 μM. α-Glucosidase-IN-82 exhibits a 52-fold increase in inhibitory activity relative to Acarbose (HY-B0089).
    α-Glucosidase-IN-82
  • HY-168465
    α-Glucosidase-IN-83 98%
    α-Glucosidase-IN-83 (compound I-1) is a potent inhibitor of α-Glucosidase, with the IC50 of 1.49 μg/mL. α-Glucosidase-IN-83 shows reduction in blood glucose levels in vivo.
    α-Glucosidase-IN-83
  • HY-168467
    Anti-obesity agent 1 98%
    Anti-obesity agent 1 (compound 4) shows potential for enhancing lipolysis, exhibiting their anti-obesity properties.
    Anti-obesity agent 1
  • HY-168481
    GLP-1R agonist 27 3086417-33-3 98%
    GLP-1R agonist 27 (compound 21) is a potent and orally active GLP-1R agonist. GLP-1R agonist 27 promots cyclic adenosine monophosphate (cAMP) accumulation. GLP-1R agonist 27 reduces blood glucose levels and food intake. GLP-1R agonist 27 has the potential for the research of obesity and type 2 diabetes mellitus (T2DM).
    GLP-1R agonist 27
  • HY-168485
    PPARα/δ agonist 3 3050611-33-8 98%
    PPARα/δ agonist 3 (Compound 8) is the orally active agonist for PPAR, that activates PPARα, PPARδ and PPARγ with EC50s of 5.6, 3.4 and 1278 nM, respectively. PPARα/δ agonist 3 exhibits anticholestatic activity in mouse ANIT- or CDCA (HY-76847)-induced cholestatic liver disease models.
    PPARα/δ agonist 3
  • HY-168495
    α-Amylase-IN-12 1799667-33-6 98%
    α-Amylase-IN-12 (Compound 5e) is an α-amylase inhibitor (IC50: 0.15 mM) with a mixed inhibition. α-Amylase-IN-12 has an IC50 of 9.40 mM against α-glucosidase. α-Amylase-IN-12 promotes glucose uptake in yeast cells and exhibits significant antiglycation activity at high concentrations. α-Amylase-IN-12 can be used for the research of diabetes.
    α-Amylase-IN-12
  • HY-168594
    α-Glucosidase/NLRP3-IN-1 98%
    α-Glucosidase/NLRP3-IN-1 (Compound 8) is a dual inhibitor of α-glucosidase and NLRP3, exhibiting an IC50 of 6.6 μM against α-glucosidase and inhibiting NLRP3 in multiple cell lines at a concentration of 100 μM. α-Glucosidase/NLRP3-IN-1 demonstrates neuroprotective and antidiabetic properties, and can be utilized in relevant research.
    α-Glucosidase/NLRP3-IN-1
  • HY-168598
    α-Amylase-IN-9 301359-47-7 98%
    α-Amylase-IN-9 (Compound 1i) is an inhibitor of α-Amylase with an IC50 value of 14.64 μM, which can be used in diabetes research.
    α-Amylase-IN-9
  • HY-168621
    DPP-4-IN-13 98%
    DPP-4-IN-13 (compound 9i) is a competitive DPP4 inhibitor with the IC50 of 9.25 μM and can be used for study of type 2 diabetes.
    DPP-4-IN-13
  • HY-168639
    AMPK activator 15 98%
    AP39 prodrug 1 (Compound M1) is a mitochondria-targeted H2S prodrug. AP39 prodrug 1 induces ROS-dependent mild mitochondrial uncoupling, activating mitochondria-associated AMPK to suppress Palmitic acid (PA) (HY-N0830)-induced lipid deposition in hepatocytes.
    AMPK activator 15
  • HY-168651
    FBPase-IN-4 98%
    FBPase-IN-4 (Compound 11 n) is a potent FBPase (Fructose-1,6-bisphosphatase) inhibitor with a Ki value of 1.78 μM. FBPase-IN-4 can be used in type 2 diabetes research.
    FBPase-IN-4
  • HY-168706
    LXQ-87 2524718-73-6 98%
    LXQ-87 is an oral noncompetitive inhibitor of PTP1B with an IC50 of 1.061 μM, showing hypoglycemic activity. LXQ-87 alleviates insulin resistance and promotes cellular glucose uptake, making it useful for research on type 2 diabetes.
    LXQ-87
  • HY-168713
    LZ-007 2920000-23-1 98%
    LZ-007 is an agonist for farnesoid X receptor (FXR) with an EC50 of 51 nM measuring by TR-FRET assay, or an EC50 of 76 nM in HepG2 cell. LZ-007 exhibits good pharmacokinetic characheristics in SD rats. LZ-007 ameliorates western diet and CCl4 (HY-Y0298)-induced mice metabolic dysfunction-associated steatohepatitis
    LZ-007
  • HY-168884
    AV457 2713387-11-0 98%
    AV457 is a potent and selective mTOR inhibitor with an IC50 value of 0.54 µM. AV457 inhibits cyst growth in polycystic kidney disease (PKD) organoids. AV457 decreases the protein expression of P-s6, P-p70s6 and don’t decreases the protein expression of P-AKT.
    AV457
  • HY-168924
    Wnt/β-catenin activator 1 98%
    Wnt/β-catenin activator 1 (Compound 5m) is the orally active activator for Wnt/β-catenin signaling pathway, that arrests cell cycle at G1 phase, inhibits early proliferation of adipocytes, and inhibits adipogenesis in cell 3T3-L1 with an IC50 of 330 nM. Wnt/β-catenin activator 1 exhibits anti-adipogenic and anti-dyslipidemic activities in high-fat diet fed Syrian golden hamster model.
    Wnt/β-catenin activator 1
  • HY-168944
    ABCB1-IN-4 1500779-21-4 98%
    ABCB1-IN-4 (Compound C6z) is an orally active and potent dual α-amylase and α-glucosidase inhibitor with IC50 values of 1.63 μM and 0.14 μM, respectively. ABCB1-IN-4 is promising for research of diabetes.
    ABCB1-IN-4
  • HY-168961
    α-Amylase/α-Glucosidase-IN-18 98%
    α-Amylase/α-Glucosidase-IN-18 (Compound 9g) is the inhibitor for α-Amylase and α-Glucosidase with IC50 of 49.17 nM and 10.71 nM. α-Amylase/α-Glucosidase-IN-18 can be used in research of type 2 diabetes mellitus.
    α-Amylase/α-Glucosidase-IN-18
  • HY-168978
    Irodanoprost 2055490-48-5 98%
    Irodanoprost is the agonist for prostaglandin receptor that can be used for research of osteogenesis-related diseases.
    Irodanoprost
  • HY-169036
    1,2-Di-13(Z)-docosenoyl-3-oleoyl-rac-glycerol 60003-02-3 98%
    1,2-Di-13(Z)-docosenoyl-3-oleoyl-rac-glycerol (1-Paimitin-2-olein-3-linolenin) is a triacylglycerol that contains 13(Z)-docosenoic acid at the sn-1 and sn-2 positions and Oleic acid (HY-N1446) at the sn-3 position.
    1,2-Di-13(Z)-docosenoyl-3-oleoyl-rac-glycerol
  • HY-169040
    28-Aminobetulin 25613-16-5 98%
    28-Aminobetulin is a pentacyclic triterpenoid and a derivative of the cholesterol biosynthesis inhibitor Betulin (HY-N0083).
    28-Aminobetulin
Cat. No. Product Name / Synonyms Application Reactivity